HopeStage
Back to all studies
TerminatedNCT01958593

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

Medication studyAges 21+Canada
The study in practice

Understand this study

Who could participate?

Listed age limits: from 21 years.

Listed locations
VancouverSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 14, 2014
Recruitment status
Terminated
Enrollment listed in the registry
6
Sponsor
Resilient Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Behavioral
Intervention type
Behavioural, Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
Over 21 Years
Official registry ID
NCT01958593
Official title
Show the full official title

A Randomized, Double-Blind, Controlled Phase 2 Pilot Study of Manualized 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in 12 Subjects With Treatment-Resistant Posttraumatic Stress Disorder (PTSD) - Canada

Recruitment & locations

Terminated

Vancouver

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Resilient Pharmaceuticals.

Does this study involve medication?

Yes. The study involves medication, including Placebo and Midomafetamine HCl.

Who can participate?

Listed age limits: from 21 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies